TY - JOUR T1 - Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis JF - Anticancer Research JO - Anticancer Res SP - 6083 LP - 6091 DO - 10.21873/anticanres.14629 VL - 40 IS - 11 AU - YU SUN AU - HIROTO NISHINO AU - NORIHIKO SUGISAWA AU - JUN YAMAMOTO AU - KAZUYUKI HAMADA AU - GUANGWEI ZHU AU - HYE IN LIM AU - ROBERT M. HOFFMAN Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6083.abstract N2 - Background/Aim: The aim of the study was to determine if oral recombinant methioninase (o-rMETase) can sensitize an orthotopic bladder tumor in nude mice to low-dose cisplatinum (CDDP). Materials and Methods: The green fluorescent protein (GFP)-expressing UM-UC-3-GFP bladder cancer was surgically orthotopically implanted (SOI) to the bladder in nude mice. The treatment was initiated when the primary tumor volume reached 100 mm3. Mice were assigned to 3 groups: G1: Saline vehicle (0.1 ml per mouse, oral, twice per day); G2: low-dose CDDP (0.5 mg/kg, intraperitoneal twice per week); G3: o-rMETase + low-dose CDDP (100 units per mouse, oral, twice per day + 0.5 mg/kg, intraperitoneal twice per week, respectively). Tumor volume and body weight were measured twice per week. The expression of Ki-67 was detected by immunohistochemistry to evaluate cell proliferation. Results: The combination of o-rMETase and low-dose CDDP increased inhibition efficacy compared to low-dose CDDP monotherapy, on primary-tumor growth (p=0.032) and metastasis (p=0.002). Conclusion: The combination of o-rMETase with low-dose CDDP has future clinical potential for bladder cancer. ER -